Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12127937 | 0.80 | ALDH1A1 (0.56) | GAAMEN1KMT2APTGS2ALDH1A1 | |
| SCHEMBL1449426 | 0.80 | ALDH1A1 (0.61) | ADORA2AADORA1GAAMEN1KMT2A | |
| SCHEMBL4293199 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1GAAMEN1KMT2A | |
| SCHEMBL4278083 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1GAAMEN1KMT2A | |
| Cyclopropane SCHEMBL15484735 | 0.76 | ADORA2A (0.77) | ADORA2AADORA1PTGS2MAPT | |
| SCHEMBL1450790 | 0.74 | ADORA2A (1.00) | ADORA2AADORA1MEN1KMT2APTGS2 | |
| SCHEMBL4279619 | 0.74 | ADORA2A (0.42) | ADORA2AADORA1GAAMEN1KMT2A | |
| SCHEMBL4285796 | 0.73 | ADORA2A (0.64) | ADORA2AADORA1GAAMEN1KMT2A | |
| SCHEMBL4283731 | 0.72 | ADORA2A (0.47) | ADORA2AADORA1GAAMEN1KMT2A | |
| SCHEMBL6229574 | 0.71 | ALDH1A1 (0.62) | GAAMEN1KMT2APTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | claimed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885GAA 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.